The crucial questions that SIMPATHY will start to address are:
- How to identify tumours that will respond?
- How to identify why some initially responsive tumours become resistant and how to avoid this or render them responsive again?
- How to transform non-responsive tumours into responsive tumours?
In order to do so the SIMPATHY proposal aims to produce a detailed map of the tumour immune microenvironment before, during and after failure of ICI treatment with the anti-PD-L1 monoclonal atezolizumab, contextualized with genomic and systemic immune features. This may allow identification of novel biomarkers across cancers of different cell origin. Recent results have shown that pre-treatment analyses may not be sufficient to predict response but that early biopsies on treatment may provide more useful information.
The context of BoB for SIMPATHY allows:
- Matched trial-grade clinical data.
- Genomic profiling of all baseline tumour samples with the Cancer Core Europe (CCE) gene panel and whole exome sequencing.
- PBMC, cfDNA analyses.
- Simple integration of further translational assays for SIMPATHY within established infrastructure, with required state-of-the-art assays available across the CCE centers.
- Experience of CCE physicians in obtaining high success rates for baseline and repeat biopsies.
- Bioinformatics expertise shared across CCE centres for data analysis.
More information: Gary Doherty, project lead, firstname.lastname@example.org